School of Pharmacy

Paul M. Beringer, PharmD

Research Interest

Cystic fibrosis is a genetic disorder which results in defective chloride transport within the apical membrane of epithelial cells throughout the body. The principal cause of morbidity and mortality arises from chronic pulmonary infections resulting in bronchiectasis and progressive loss of lung function and eventual respiratory failure. Our group is interested in optimizing the use of pharmacologic therapies to preserve lung function and quality of life for individuals afflicted with CF.

Ongoing research projects include: the study of the mechanistic basis of the enhanced renal clearance of antibiotics in CF; the use of novel clinical measures of glomerular filtration to improve drug dosing; and impact of pancreatic insufficiency on oral bioavailability of antibiotics.

Biography

Dr. Beringer received his Pharm.D. degree from the USC School of Pharmacy. He completed a pharmacy practice residency and specialty residency in pharmacokinetics at the University of California at San Francisco. Currently, he is an associate professor of clinical pharmacy (USC School of Pharmacy) and associate professor of clinical medicine with the department of pulmonary and critical care medicine (USC Keck School of Medicine).

Dr. Beringer's clinical expertise is in the area of cystic fibrosis pharmacotherapy. He has authored numerous journal articles and book chapters in the area of pharmacokinetics and cystic fibrosis.

Click here for:

PubMed Search — Research Contracts & Grants

Research Support

Principal Investigator - Renal P-gp: Contribution to the Enhanced Clearance of Antibiotics in Patients with Cystic Fibrosis. Sponsor: ACCP Career Development Research Award

Selected Projects/Publications

Aminimanizani A, Beringer PM, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone agents. Clin Pharmacokinet 2001;40:169-87.

Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro B, Jelliffe R, Gill MA. Population Pharmacokinetics and use of Monte Carlo simulation to determine the optimal dose of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2001;45:3468-73.

Beringer PM, Aminimanizani A, Scott C, Synold T. Development of population pharmacokinetic models and optimal sampling times for ibuprofen in children with cystic fibrosis. Ther Drug Monitor 2002.